BTAI - Company ID 0001720893
The table below shows BioXcel Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$11.81M | -$12.04M | -$17.71M | -$52.35M | -$32.41M | -$19.64M |
| Capital expenditure | $0.00 | $0.00 | - | - | $120.00K | $316.00K |
| Investing cash flow | $0.00 | $0.00 | - | - | -$120.00K | -$316.00K |
| Dividends paid | - | - | - | - |
BioXcel Therapeutics, Inc. reported operating cash flow of -$57.62M for fiscal year 2025. That is up 20.0% from -$72.03M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$2.20M (FY 2017) to -$57.62M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $232.00K | $13.20M | $26.63M | $24.15M | - | $852.00K |